MARKETS
Markets

Radiopharm Theranostics Announces $4.1M U.S. Direct Offering Of Shares And Warrants Along With A$12.7M ($8.9M) Australian Placement

Jul 24, 2026 · 07:18 AM ET· updated 2h ago

Radiopharm Theranostics Limited (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas

Share
Why It Matters

Radiopharm Theranostics raised money by selling new shares and special purchase rights to investors in the U.S. and Australia. When a company does this, it means they need cash to keep working on their medicines, so watch whether their science is actually moving forward.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.